Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd at 4:30 p.m. ET.
https://mma.prnewswire.com/media/1273133/Dynavax_Logo.jpg
The presentations will be webcast and may be accessed through the “Events & Presentations” page on the “Investors” section of the Company's website athttps://investors.dynavax.com/events-presentations.
AboutDynavaxDynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visitwww.dynavax.com.
For Investors/Media:Paul Coxpcox@dynavax.com510-665-0499
NicoleArndtnarndt@dynavax.com510-665-7264
https://c212.net/c/img/favicon.png?sn=SF60522&sd=2025-08-27
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-participate-in-the-2025-wells-fargo-healthcare-conference-302540380.html
SOURCE Dynavax Technologies
https://rt.newswire.ca/rt.gif?NewsItemId=SF60522&Transmission_Id=202508271605PR_NEWS_USPR_____SF60522&DateId=20250827